These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 27653543)

  • 1. M2-based influenza vaccines: recent advances and clinical potential.
    Kolpe A; Schepens B; Fiers W; Saelens X
    Expert Rev Vaccines; 2017 Feb; 16(2):123-136. PubMed ID: 27653543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e.
    Park KS; Seo YB; Lee JY; Im SJ; Seo SH; Song MS; Choi YK; Sung YC
    Vaccine; 2011 Jul; 29(33):5481-7. PubMed ID: 21664216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.
    Tsybalova LM; Stepanova LA; Kuprianov VV; Blokhina EA; Potapchuk MV; Korotkov AV; Gorshkov AN; Kasyanenko MA; Ravin NV; Kiselev OI
    Vaccine; 2015 Jun; 33(29):3398-406. PubMed ID: 25976545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant loop region of hepatitis B core antigen: Insertion of multiple copies of M2e increases immunogenicity and protective efficiency.
    Ravin NV; Blokhina EA; Kuprianov VV; Stepanova LA; Shaldjan AA; Kovaleva AA; Tsybalova LM; Skryabin KG
    Vaccine; 2015 Jun; 33(29):3392-7. PubMed ID: 25937448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineering of the PapMV vaccine platform with a shortened M2e peptide leads to an effective one dose influenza vaccine.
    Carignan D; Thérien A; Rioux G; Paquet G; Gagné ML; Bolduc M; Savard P; Leclerc D
    Vaccine; 2015 Dec; 33(51):7245-7253. PubMed ID: 26549362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments.
    Schotsaert M; De Filette M; Fiers W; Saelens X
    Expert Rev Vaccines; 2009 Apr; 8(4):499-508. PubMed ID: 19348565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and protective efficacy of the norovirus P particle-M2e chimeric vaccine in chickens.
    Elaish M; Kang KI; Xia M; Ali A; Shany SA; Wang L; Jiang X; Lee CW
    Vaccine; 2015 Sep; 33(38):4901-9. PubMed ID: 26232342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant baculovirus vaccine containing multiple M2e and adjuvant LTB induces T cell dependent, cross-clade protection against H5N1 influenza virus in mice.
    Zhang J; Fan HY; Zhang Z; Zhang J; Zhang J; Huang JN; Ye Y; Liao M
    Vaccine; 2016 Jan; 34(5):622-629. PubMed ID: 26724200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination with different M2e epitope densities confers partial protection against H5N1 influenza A virus challenge in chickens.
    Zhang X; Liu M; Liu C; Du J; Shi W; Sun E; Li H; Li J; Zhang Y
    Intervirology; 2011; 54(5):290-9. PubMed ID: 21228535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. M2e-based universal influenza A vaccine.
    Fiers W; De Filette M; El Bakkouri K; Schepens B; Roose K; Schotsaert M; Birkett A; Saelens X
    Vaccine; 2009 Oct; 27(45):6280-3. PubMed ID: 19840661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin.
    Huleatt JW; Nakaar V; Desai P; Huang Y; Hewitt D; Jacobs A; Tang J; McDonald W; Song L; Evans RK; Umlauf S; Tussey L; Powell TJ
    Vaccine; 2008 Jan; 26(2):201-14. PubMed ID: 18063235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran.
    Ebrahimi SM; Dabaghian M; Tebianian M; Jazi MH
    Virology; 2012 Aug; 430(1):63-72. PubMed ID: 22595444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection against influenza A virus by vaccination with a recombinant fusion protein linking influenza M2e to human serum albumin (HSA).
    Mu X; Hu K; Shen M; Kong N; Fu C; Yan W; Wei A
    J Virol Methods; 2016 Feb; 228():84-90. PubMed ID: 26615805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective efficacy of a bacterially produced modular capsomere presenting M2e from influenza: extending the potential of broadly cross-protecting epitopes.
    Wibowo N; Hughes FK; Fairmaid EJ; Lua LH; Brown LE; Middelberg AP
    Vaccine; 2014 Jun; 32(29):3651-5. PubMed ID: 24795225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a heat-stable and orally delivered recombinant M2e-expressing B. subtilis spore-based influenza vaccine.
    Zhao G; Miao Y; Guo Y; Qiu H; Sun S; Kou Z; Yu H; Li J; Chen Y; Jiang S; Du L; Zhou Y
    Hum Vaccin Immunother; 2014; 10(12):3649-58. PubMed ID: 25483702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant M2e outer membrane vesicle vaccines protect against lethal influenza A challenge in BALB/c mice.
    Rappazzo CG; Watkins HC; Guarino CM; Chau A; Lopez JL; DeLisa MP; Leifer CA; Whittaker GR; Putnam D
    Vaccine; 2016 Mar; 34(10):1252-8. PubMed ID: 26827663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tandem repeats of the extracellular domain of Matrix 2 influenza protein exposed in Brucella lumazine synthase decameric carrier molecule induce protection in mice.
    Alvarez P; Zylberman V; Ghersi G; Boado L; Palacios C; Goldbaum F; Mattion N
    Vaccine; 2013 Jan; 31(5):806-12. PubMed ID: 23246552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved design and intranasal delivery of an M2e-based human influenza A vaccine.
    De Filette M; Fiers W; Martens W; Birkett A; Ramne A; Löwenadler B; Lycke N; Jou WM; Saelens X
    Vaccine; 2006 Nov; 24(44-46):6597-601. PubMed ID: 16814430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress on adenovirus-vectored universal influenza vaccines.
    Xiang K; Ying G; Yan Z; Shanshan Y; Lei Z; Hongjun L; Maosheng S
    Hum Vaccin Immunother; 2015; 11(5):1209-22. PubMed ID: 25876176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunogenicity of recombinant proteins including ectodomain of M2 influenza virus A].
    Stepanova LA; Kovaleva AA; Potapchuk MV; Korotkov AV; Kupriianov VV; Blokhina EA; Kotliarov RIu; Tsybalova LM
    Vopr Virusol; 2013; 58(3):21-5. PubMed ID: 24006628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.